Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

SHARYN N LEWIN

Allopathic & Osteopathic Physicians Obstetrics & Gynecology Gynecologic Oncology

NPI
1083862247
CMS profile
564788
Location
TEANECK, NJ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$202,299.16

170 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

By paying entity

PY2024 · entire year · sorted by reported total

Paying entityAmountRecords
AstraZeneca Pharmaceuticals LP $104,391.37 90
GlaxoSmithKline, LLC. $53,875.09 41
ABBVIE INC. $30,921.68 25
Merck Sharp & Dohme LLC $6,690.00 4
Eisai Inc. $2,484.99 3
Myriad Genetic Laboratories, Inc. $2,168.64 5
ImmunoGen, Inc. $1,754.00 1
Cumberland Pharmaceuticals, Inc. $13.39 1

Page 3 of 4; records 101–150 of 170 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

SHARYN N LEWIN

NPI 1083862247 · CMS profile ID 564788

Allopathic & Osteopathic Physicians / Obstetrics & Gynecology / Gynecologic Oncology

TEANECK, NJ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 4; records 101–150 of 170 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1083862247?year=2024&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
SHARYN N LEWIN, NPI 1083862247, CMS profile ID 564788. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 170 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1083862247?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). SHARYN N LEWIN, NPI 1083862247, CMS profile ID 564788. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 170 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1083862247?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
SHARYN N LEWIN, NPI 1083862247, CMS profile ID 564788, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 4; records 101–150 of 170 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1083862247?year=2024&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

170 matching records · $202,299.16 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 170 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 170.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AstraZeneca Pharmaceuticals LP $1,050.0005/08/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104250079 CMS
AstraZeneca Pharmaceuticals LP $15.6205/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105502050 CMS
GlaxoSmithKline, LLC. $848.3004/30/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116401983 CMS
GlaxoSmithKline, LLC. $70.8104/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116448044 CMS
GlaxoSmithKline, LLC. $124.9304/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116546605 CMS
ABBVIE INC. $3,854.0004/29/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103160714 CMS
ABBVIE INC. $28.0104/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104169084 CMS
ABBVIE INC. $66.5304/29/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104193624 CMS
ABBVIE INC. $56.9504/29/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104193626 CMS
AstraZeneca Pharmaceuticals LP $16.2104/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105779066 CMS
GlaxoSmithKline, LLC. $125.0004/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116430081 CMS
GlaxoSmithKline, LLC. $977.5604/24/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116551795 CMS
GlaxoSmithKline, LLC. $125.0004/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116659291 CMS
AstraZeneca Pharmaceuticals LP $2,750.0004/15/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104777450 CMS
ABBVIE INC. $95.5004/11/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104193620 CMS
ABBVIE INC. $55.9904/11/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104193622 CMS
AstraZeneca Pharmaceuticals LP $14.7404/11/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104294516 CMS
AstraZeneca Pharmaceuticals LP $121.3504/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105397106 CMS
ABBVIE INC. $3,854.0004/10/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103160712 CMS
ABBVIE INC. $124.7704/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104169082 CMS
AstraZeneca Pharmaceuticals LP $5,500.0004/09/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105626877 CMS
AstraZeneca Pharmaceuticals LP $1,350.0004/05/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105869147 CMS
GlaxoSmithKline, LLC. $2,400.0004/03/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116452169 CMS
AstraZeneca Pharmaceuticals LP $4,110.0003/18/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105255302 CMS
AstraZeneca Pharmaceuticals LP $16.0203/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105525537 CMS
AstraZeneca Pharmaceuticals LP $107.6303/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104465058 CMS
AstraZeneca Pharmaceuticals LP $888.5603/14/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104570412 CMS
ABBVIE INC. $9,980.0603/13/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103136871 CMS
AstraZeneca Pharmaceuticals LP $46.3003/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104325850 CMS
AstraZeneca Pharmaceuticals LP $535.7803/05/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104460214 CMS
AstraZeneca Pharmaceuticals LP $5,500.0003/05/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105601023 CMS
AstraZeneca Pharmaceuticals LP $2,050.0003/05/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105731641 CMS
AstraZeneca Pharmaceuticals LP $221.6403/04/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104264657 CMS
AstraZeneca Pharmaceuticals LP $6.5003/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104336890 CMS
AstraZeneca Pharmaceuticals LP $374.1803/04/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104591174 CMS
AstraZeneca Pharmaceuticals LP $166.6603/04/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105610169 CMS
AstraZeneca Pharmaceuticals LP $29.8903/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104421159 CMS
AstraZeneca Pharmaceuticals LP $237.3002/29/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104404553 CMS
AstraZeneca Pharmaceuticals LP $56.6702/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104432285 CMS
AstraZeneca Pharmaceuticals LP $406.1102/29/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104553978 CMS
AstraZeneca Pharmaceuticals LP $346.6802/29/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104620098 CMS
AstraZeneca Pharmaceuticals LP $113.3102/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105691291 CMS
ABBVIE INC. $13.8502/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104169080 CMS
AstraZeneca Pharmaceuticals LP $5,500.0002/28/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105503890 CMS
AstraZeneca Pharmaceuticals LP $1,350.0002/27/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104515420 CMS
AstraZeneca Pharmaceuticals LP $1,024.7802/21/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104400085 CMS
AstraZeneca Pharmaceuticals LP $97.6802/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105773344 CMS
AstraZeneca Pharmaceuticals LP $685.0002/20/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104273811 CMS
AstraZeneca Pharmaceuticals LP $5,500.0002/20/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105636784 CMS
ABBVIE INC. $71.0102/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104169076 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $81,256.92 85
PY2020 $45,873.07 48
PY2021 $124,864.47 95
PY2022 $155,208.82 128
PY2023 $200,107.71 232
PY2024 $202,299.16 170
PY2025 $158,397.03 117

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $128,977.40 24
PY2024 Principal investigator $67,171.04 40
PY2023 Principal investigator $272,934.51 37
PY2022 Principal investigator $197,935.31 13
PY2021 Principal investigator $236,352.86 15
PY2020 Principal investigator $441,596.13 44
PY2019 Principal investigator $310,937.37 48

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

24 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $966.00 12/31/2025 Non-covered Recipient Entity
HOLY NAME MEDICAL CENTER
A Phase 1, First-in-Human, Open-Label, Dose-Escalation and Expansion Study of IMGN151 (Anti-FR Antibody-drug Conjugate) in Adult Patients With Recurrent Gynaecological Cancers No dispute reported 06/30/2026 1202534971
Principal investigator 1 Merck Sharp & Dohme LLC $10,476.70 12/31/2025 Non-covered Recipient Entity
Holy Name Medical Center
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001 No dispute reported 06/30/2026 1232936752
Principal investigator 1 GlaxoSmithKline, LLC. $905.58 12/24/2025 Non-covered Recipient Entity
HOLY NAME HOSPITAL
A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA No dispute reported 06/30/2026 1192116535
Principal investigator 1 Genmab U.S., Inc. $5,272.80 12/16/2025 Non-covered Recipient Entity
HOLY NAME MEDICAL CENTER
A Phase 3 Randomized, Open-label Study of Rinatabart Sesutecan (Rina-S) Versus Treatment of Investigator's Choice (IC) in Patients With Platinum Resistant Ovarian Cancer No dispute reported 06/30/2026 1235930629
Principal investigator 1 ABBVIE INC. $6,420.33 12/04/2025 Non-covered Recipient Entity
HOLY NAME MEDICAL CENTER
Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Ovarian, Fallopian Tube, or Peritoneal Cancer (GLORIOSA) No dispute reported 06/30/2026 1202526628
Principal investigator 1 ABBVIE INC. $4,515.00 12/01/2025 Non-covered Recipient Entity
HOLY NAME MEDICAL CENTER
Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Ovarian, Fallopian Tube, or Peritoneal Cancer (GLORIOSA) No dispute reported 06/30/2026 1202526158
Principal investigator 1 ABBVIE INC. $4,515.00 12/01/2025 Non-covered Recipient Entity
HOLY NAME MEDICAL CENTER
Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Ovarian, Fallopian Tube, or Peritoneal Cancer (GLORIOSA) No dispute reported 06/30/2026 1202526160
Principal investigator 1 Daiichi Sankyo Inc. $78.90 12/01/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
DS600-109 No dispute reported 06/30/2026 1223350324
Principal investigator 1 Daiichi Sankyo Inc. $78.90 12/01/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
DS600-109 No dispute reported 06/30/2026 1223350326
Principal investigator 1 Daiichi Sankyo Inc. $78.90 12/01/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
DS600-109 No dispute reported 06/30/2026 1223350328
Principal investigator 1 Daiichi Sankyo Inc. $78.90 12/01/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
DS600-109 No dispute reported 06/30/2026 1223350330
Principal investigator 1 Daiichi Sankyo Inc. $106.20 12/01/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
DS600-109 No dispute reported 06/30/2026 1223350332
Principal investigator 1 Daiichi Sankyo Inc. $78.90 12/01/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
DS600-109 No dispute reported 06/30/2026 1223350334
Principal investigator 1 Daiichi Sankyo Inc. $52.60 12/01/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
DS600-109 No dispute reported 06/30/2026 1223350336
Principal investigator 1 Daiichi Sankyo Inc. $78.90 12/01/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
DS600-109 No dispute reported 06/30/2026 1223350338
Principal investigator 1 Daiichi Sankyo Inc. $35,000.00 10/29/2025 Non-covered Recipient Entity
Holy Name Medical Center
DS600-109 No dispute reported 06/30/2026 1223369229
Principal investigator 1 ABBVIE INC. $6,383.50 09/25/2025 Non-covered Recipient Entity
HOLY NAME MEDICAL CENTER INC
Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FR) Expressing, Platinum-sensitive Epithelial Ovarian Cancer No dispute reported 06/30/2026 1202512444
Principal investigator 1 Genmab U.S., Inc. $5,071.30 09/25/2025 Non-covered Recipient Entity
HOLY NAME MEDICAL CENTER
A Phase 3 Randomized, Open-label Study of Rinatabart Sesutecan (Rina-S) Versus Treatment of Investigator's Choice (IC) in Patients With Platinum Resistant Ovarian Cancer No dispute reported 06/30/2026 1235930620
Principal investigator 1 ABBVIE INC. $100.00 09/04/2025 Non-covered Recipient Entity
HOLY NAME MEDICAL CENTER INC
A Phase 1, First-in-Human, Open-Label, Dose-Escalation and Expansion Study of IMGN151 (Anti-FR Antibody-drug Conjugate) in Adult Patients With Recurrent Gynaecological Cancers No dispute reported 06/30/2026 1202510104
Principal investigator 1 ABBVIE INC. $4,805.25 07/22/2025 Non-covered Recipient Entity
HOLY NAME MEDICAL CENTER
Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Ovarian, Fallopian Tube, or Peritoneal Cancer (GLORIOSA) No dispute reported 06/30/2026 1202499130
Principal investigator 1 Genmab U.S., Inc. $4,869.80 07/10/2025 Non-covered Recipient Entity
HOLY NAME MEDICAL CENTER
A Phase 3 Randomized, Open-label Study of Rinatabart Sesutecan (Rina-S) Versus Treatment of Investigator's Choice (IC) in Patients With Platinum Resistant Ovarian Cancer No dispute reported 06/30/2026 1235930624
Principal investigator 1 Daiichi Sankyo Inc. $43.94 07/01/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
DS600-109 No dispute reported 06/30/2026 1223350322
Principal investigator 1 ABBVIE INC. $4,000.00 04/02/2025 Non-covered Recipient Entity
HOLY NAME MEDICAL CENTER
Mirvetuximab Soravtansine Monotherapy in Platinum-Sensitive Epithelial, Peritoneal, and Fallopian Tube Cancers (PICCOLO) No dispute reported 06/30/2026 1202468592
Principal investigator 1 Genmab U.S., Inc. $35,000.00 03/17/2025 Non-covered Recipient Entity
HOLY NAME MEDICAL CENTER
A Phase 3 Randomized, Open-label Study of Rinatabart Sesutecan (Rina-S) Versus Treatment of Investigator's Choice (IC) in Patients With Platinum Resistant Ovarian Cancer No dispute reported 06/30/2026 1235930633